None listed
Conditions
Brief summary
Ischaemic stroke may affect a number of hormone pathways involving the pituitary gland in the brain, including the production of human growth hormone (HGH). Disruption of HGH production may contribute to a number of the long-term clinical symptoms experienced by stroke survivors. This study aims to investigate whether HGH deficiency is common in stroke survivors. This is a hypothesis-generating pilot study which may lead to bigger studies in the future.
Interventions
No interventions are being tested. One-off investigation of each participant's HGH levels will be conducted by a baseline blood sample and repeated blood samples at 15 minute intervals over 75 minutes after a single injection of arginine (500mg/Kg up to a maximum dose of 30000mg) and human growth hormone releasing hormone (1microgram/Kg up to a maximum dose of 100 micrograms).
Sponsors
John Hunter Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Diagnosis
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Ischemic stroke within 5 years. 18 years of age or older Modified Rankin Score (mRS) of 3 or less Can speak reasonable English, understand instructions and be able to complete tests and questionnaires on their own or with minimal support Able to give informed consent
Exclusion criteria
pre-existing depression, dementia or other neuropsychiatric disease stroke induced by trauma, infection or surgery current or past drug abuse known active malignancy, any intracranial tumor, subdural or epidural hematoma renal or hepatic impairment use of benzodiazepines or antiepileptic drugs patients on immunosuppression or known immunodeficiency state e.g. HIV
Outcome results
None listed